Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry (BSC, NCEH/ATSDR), Lead Poisoning Prevention (LPP) Subcommittee, 23250-23251 [2017-10333]
Download as PDF
23250
Federal Register / Vol. 82, No. 97 / Monday, May 22, 2017 / Notices
obligations, these statutory provisions
provide the legal authorization for the
collection of information on the FR
3016. The FR 3016 is a voluntary
survey. No issue of confidentiality
normally arises under the FR 3016, as
names and any other characteristics that
would permit personal identification of
respondents are not reported to the
Board. However, should the Board
obtain such information, it would likely
be exempt under exemption 6 of the
Freedom of Information Act (5 U.S.C.
552(b)(6)) to the extent that it includes
‘‘personnel and medical files and
similar files the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.’’
Board of Governors of the Federal Reserve
System, May 17, 2017.
Ann E. Misback,
Secretary of the Board.
[FR Doc. 2017–10331 Filed 5–19–17; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on DSK30JT082PROD with NOTICES
Subcommittee for Dose
Reconstruction Reviews (SDRR),
Advisory Board on Radiation and
Worker Health (ABRWH or the
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting for the
aforementioned subcommittee:
Time and Date: 10:30 a.m.–5:00 p.m.,
EDT, June 27, 2017.
Place: Audio Conference Call via FTS
Conferencing.
Status: Open to the public, but
without a public comment period. The
public is welcome to submit written
comments in advance of the meeting, to
the contact person below. Written
comments received in advance of the
meeting will be included in the official
record of the meeting. The public is also
welcome to listen to the meeting by
joining the teleconference at the USA
toll-free, dial-in number at 1–866–659–
0537 and the pass code is 9933701.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
VerDate Sep<11>2014
23:17 May 19, 2017
Jkt 241001
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that
have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to CDC. NIOSH
implements this responsibility for CDC.
The charter was issued on August 3,
2001, renewed at appropriate intervals,
rechartered on March 22, 2016 pursuant
to Executive Order 13708, and will
expire on September 30, 2017.
Purpose: The Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class. The
Subcommittee for Dose Reconstruction
Reviews was established to aid the
Advisory Board in carrying out its duty
to advise the Secretary, HHS, on dose
reconstruction.
Matters for Discussion: The agenda for
the Subcommittee meeting includes the
following dose reconstruction program
quality management and assurance
activities: Dose reconstruction cases
under review from Sets 14–23,
including the Oak Ridge sites (Y–12, K–
25, Oak Ridge National Laboratory),
Hanford, Feed Materials Production
Center (‘‘Fernald’’), Mound Plant, Rocky
Flats Plant, Nevada Test Site, Idaho
National Laboratory, Savannah River
Site, and other Department of Energy
and ‘‘Atomic Weapons Employer’’
facilities.
The agenda is subject to change as
priorities dictate.
Contact Person for More Information:
Theodore Katz, Designated Federal
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
Officer, NIOSH, CDC, 1600 Clifton
Road, Mailstop E–20, Atlanta, Georgia
30333, Telephone (513) 533–6800, Toll
Free 1(800)CDC–INFO, Email ocas@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–10332 Filed 5–19–17; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
Board of Scientific Counselors,
National Center for Environmental
Health/Agency for Toxic Substances
and Disease Registry (BSC, NCEH/
ATSDR), Lead Poisoning Prevention
(LPP) Subcommittee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the CDC, National
Center for Environmental Health/
Agency for Toxic Substances and
Disease Registry (NCEH/ATSDR)
announces the following meeting of the
aforementioned committee:
Time and date: 9:00 a.m.–12:00 p.m.
EDT, June 23, 2017.
Place: The meeting will be accessible
by teleconference. Please dial toll free
1–888–790–2009 Passcode: 7865774.
Status: Open to the public, via
teleconference line. No limit on number
of lines. The public is welcome to
participate during the Public Comment
period which is scheduled from 11:00
a.m. until 11:15 a.m. EST (15 minutes).
Individuals wishing to make a comment
during Public Comment period, please
email your name, organization, and
phone number by Monday, June 15,
2017 to Amanda Malasky at AMalasky@
cdc.gov.
Purpose: The subcommittee will
discuss strategies and options on ways
to prioritize NCEH/ATSDR’s activities,
improve health outcomes, and address
health disparities as it relates to lead
exposures. The subcommittee will
deliberate on ways to evaluate lead
exposure and how to best conduct
health evaluations through exposure
E:\FR\FM\22MYN1.SGM
22MYN1
Federal Register / Vol. 82, No. 97 / Monday, May 22, 2017 / Notices
and epidemiologic studies.
Subcommittee proposals on lead
prevention practices and national lead
poisoning prevention efforts will be
provided to the Board of Scientific
Counselors for deliberation and possible
adoption as formal recommendations to
NCEH/ATSDR.
Matters for Discussion: Agenda items
will include the following: Lead
Poisoning Prevention Program (status),
Flint Registry (status), Revision of Blood
Lead Level reference value (status),
Discussion of legislative requirements of
a new Lead Exposure and Prevention
Federal Advisory Committee, Federal
partnership efforts.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Amanda Malasky, Coordinator, Lead
Poisoning Prevention Subcommittee,
BSC, NCEH/ATSDR, 4770 Buford
Highway, Mail Stop F–45, Chamblee,
Georgia 30345; telephone 770/488–
7699, Fax: 770/488–3377; Email:
AMalasky@cdc.gov.
The Director, Management Analysis
and Services Office has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–10333 Filed 5–19–17; 8:45 am]
announcement and matters for
discussion should read as follows:
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcement (FOA)
GH17–005, Conducting Public Health
Research in China.
Time and Date: 9:00 a.m.–2:00 p.m.,
EDT, May 24, 2017
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Conducting Public Health Research in
China’’, GH17–005.
FOR FURTHER INFORMATION CONTACT:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road,
NE., Mailstop D–69, Atlanta, Georgia
30033, Telephone: (404) 639–4796,
CGHERPO@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–10334 Filed 5–19–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Centers for Disease Control and
Prevention
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of
Meeting; Establishment of a Public
Docket; Request for Comments
[Docket No. FDA–2017–N–1988]
mstockstill on DSK30JT082PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
AGENCY:
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcement (FOA)
GH16–006, Conducting Public Health
Research in Kenya; GH17–004,
Conducting Public Health Research
Activities in Egypt; GH17–005,
Conducting Public Health Research in
China.
This publication corrects a notice that
was published in the Federal Register
on May 4, 2017, Volume 82, Number 85,
pages 20894–20895. The meeting
VerDate Sep<11>2014
23:17 May 19, 2017
Jkt 241001
Food and Drug Administration,
HHS.
Notice; establishment of a
public docket; request for comments.
ACTION:
The Food and Drug
Administration (FDA or Agency)
announces a forthcoming public
advisory committee meeting of the
Endocrinologic and Metabolic Drugs
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public. FDA
is establishing a docket for public
comment on this document.
SUMMARY:
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
23251
The meeting will be held on June
20, 2017, from 8 a.m. to 5 p.m.
Comments received on or before June 6,
2017, will be provided to the committee.
Comments received after that date will
be taken into consideration by the
Agency.
DATES:
FDA White Oak Campus,
10903 New Hampshire Avenue,
Building. 31 Conference Center, the
Great Room (Rm. 1503), Silver Spring,
MD 20993–0002. Answers to commonly
asked questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm408555.htm.
FDA is establishing a docket for
public comment on this meeting. The
docket number is FDA–2017–N–1988.
All submissions received must include
the Docket No. FDA–2017–N–1988 for
‘‘Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments.’’ For detailed
instructions on sending comments, see
the ‘‘Public Participation’’ heading of
the SUPPLEMENTARY INFORMATION section
of this document. You may submit
comments as follows:
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov/. Follow
the instructions for submitting
comments. Comments submitted
electronically, including attachments, to
https://www.regulations.gov/ will be
posted to the docket unchanged.
Because your comment will be made
public, you are solely responsible for
ensuring that your comment does not
include any confidential information
that you or a third party may not wish
to be posted, such as medical
information, your or anyone else’s
Social Security number, or confidential
business information, such as a
manufacturing process. Please note that
if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov/.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
E:\FR\FM\22MYN1.SGM
22MYN1
Agencies
[Federal Register Volume 82, Number 97 (Monday, May 22, 2017)]
[Notices]
[Pages 23250-23251]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10333]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention (CDC)
Board of Scientific Counselors, National Center for Environmental
Health/Agency for Toxic Substances and Disease Registry (BSC, NCEH/
ATSDR), Lead Poisoning Prevention (LPP) Subcommittee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the CDC, National Center for
Environmental Health/Agency for Toxic Substances and Disease Registry
(NCEH/ATSDR) announces the following meeting of the aforementioned
committee:
Time and date: 9:00 a.m.-12:00 p.m. EDT, June 23, 2017.
Place: The meeting will be accessible by teleconference. Please
dial toll free 1-888-790-2009 Passcode: 7865774.
Status: Open to the public, via teleconference line. No limit on
number of lines. The public is welcome to participate during the Public
Comment period which is scheduled from 11:00 a.m. until 11:15 a.m. EST
(15 minutes). Individuals wishing to make a comment during Public
Comment period, please email your name, organization, and phone number
by Monday, June 15, 2017 to Amanda Malasky at AMalasky@cdc.gov.
Purpose: The subcommittee will discuss strategies and options on
ways to prioritize NCEH/ATSDR's activities, improve health outcomes,
and address health disparities as it relates to lead exposures. The
subcommittee will deliberate on ways to evaluate lead exposure and how
to best conduct health evaluations through exposure
[[Page 23251]]
and epidemiologic studies. Subcommittee proposals on lead prevention
practices and national lead poisoning prevention efforts will be
provided to the Board of Scientific Counselors for deliberation and
possible adoption as formal recommendations to NCEH/ATSDR.
Matters for Discussion: Agenda items will include the following:
Lead Poisoning Prevention Program (status), Flint Registry (status),
Revision of Blood Lead Level reference value (status), Discussion of
legislative requirements of a new Lead Exposure and Prevention Federal
Advisory Committee, Federal partnership efforts.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Amanda Malasky, Coordinator,
Lead Poisoning Prevention Subcommittee, BSC, NCEH/ATSDR, 4770 Buford
Highway, Mail Stop F-45, Chamblee, Georgia 30345; telephone 770/488-
7699, Fax: 770/488-3377; Email: AMalasky@cdc.gov.
The Director, Management Analysis and Services Office has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-10333 Filed 5-19-17; 8:45 am]
BILLING CODE 4163-18-P